ttention-deficit/hyperactivity disorder (ADHD) is characterized by problems regulating attention and controlling behavior across social settings.
particularly daunting. The available evidence upon which clinical decisions for new drugs are based often consists of results from clinical trials evaluating short-term efficacy in highly selected populations. While such trials are critical in establishing a drug' s efficacy prior to approval, trial populations and care delivery are often not representative of real-world clinical practice. 10 This creates an information vacuum in the early days following a drug' s approval. Later, providers learn from practical clinical experience and additional studies which patients are best suited for the new agent. For instance, an interim open-label study was recently published that enrolled the patients from the initial short-term ATX trials. With a mean treatment length of 40 weeks, longer duration efficacy and safety data were added to the knowledge about ATX. 11 Until longer-term clinical trial data for ATX become available, examining emerging patterns of medication use may be informative for care of adult ADHD. Differences in treatment selection reflect not only marketing efforts but perceived medication successes and failures over time. In addition to providing clues as to where the drug may be most useful, managed care decision makers may find information on emerging patterns useful in deciding if use of a new product appears to be meeting previously unmet needs (versus being used interchangeably with existing and usually less costly therapies). From a risk surveillance perspective, understanding which patients are being selected for specific treatments may help provide important context in the event that adverse consequences become apparent. For instance, adverse events may be directly related to drug effects, but they also may be the result of increased baseline risk in the treatment group compared with baseline risk in the group receiving traditional therapy.
Three years after the introduction of ATX, administrative claims data are available to allow study of the early utilization patterns of ATX relative to STIM use for ADHD. We hypothesized that the use of ATX would be preferred in (1) patients with conditions that may be exacerbated by STIMs, such as tics and anxiety; (2) patients for whom present substance abuse is a concern, such as those with a history of alcohol or substance abuse; and (3) difficult-to-treat or treatment-refractory patients, such as those with comorbid psychiatric disorders (e.g., depression, psychosis, or personality disorders) or a recent history of nonpharmacological mental health treatment. In this article, we focus specifically on adults with ADHD. A similar examination in children of ATX versus STIM and long-acting stimulant (LA-STIM) use has been published previously. 12 
■■ Methods
The current analyses were limited to adults (aged >18 years) because treatment priorities, diagnosis, and the importance of certain medication side effects are different for adults and children with ADHD. We focused on the examination of multiple demographic, diagnostic, and treatment factors preceding initiations of ATX and STIMs. Although bupropion and tricyclic antidepressants have been successfully used in adult ADHD and are commonly used as second-line agents, 13, 14 our study design intentionally excluded these drugs from the analysis since they are not approved by the FDA for the treatment of ADHD. Specific STIM medications and their categorizations are shown in Table 1 and are based upon the categorizations described by the Subcommittee on Attention-Deficit/Hyperactivity Disorder of the American Academy of Pediatrics' Committee on Quality Improvement. 15, 16 Because we were assessing the pattern of treatment in the year of ATX' s introduction and because patient care often involves more than one agent over the course of time, we compared treatments based on the most recent treatment initiation for each patient. Since ATX is considered long-acting, we compared recent initiations of ATX with those of STIMs in general and with LA-STIMs specifically. This division into 2 sets of analyses created some replication of findings for STIMs as a class but also allowed for a more direct comparison between treatments of similar cost; the shorter-acting medications are readily available generically, and, thus, findings here may reflect the effect of confounding socioeconomic or other factors. Where findings are repeated across analyses, we have greater confidence that the findings are the result of differences in treatment approach rather than access per se.
Our data were drawn from the proprietary PharMetrics database. At the time of the study, this database consisted of administrative health care claims data from more than 75 We defined a treatment "initiation" as a new prescription for an ADHD medication preceded by 3 months without similar therapy. The 3-month interval was chosen for consistency with our prior study of children, 12 in which we acknowledged that gaps in treatment may occur during summer months even through college years. ATX was only first widely available in January 2003. To reduce the potential for a systematic bias related to the inclusion of very early adopters, treatment episodes were included with the first date between April 1, 2003, and December 31, 2003. Because "concurrent start" episodes (e.g., a patient's having a qualifying treatment initiation for methylphenidate and ATX on the same day) could not be clearly assigned to only 1 comparison group, these patients were excluded from our analyses.
Pharmacy claims for ATX and STIMs were examined. STIMs with 8 to 12 hours duration of action were separately examined by comparing initiations of ATX with those of LA-STIMs in separate statistical models. A new treatment initiation was defined as a prescription for a categorized medication preceded by 3 months without that same medication or any other medication within the same treatment category (ATX, STIM, or LA-STIM). For example, a prescription for Concerta (long-acting methylphenidate) would constitute a LA-STIM initiation if, for the 3 months preceding that prescription, the patient was enrolled in the plan but showed no claim for Concerta or any other LA-STIM. This patient could, however, have received a short-acting STIM such as immediate-release (IR) methylphenidate; in that case, the prior short-acting STIM use would appear as a predictor for LA-STIM treatment initiation. In contrast, a STIM episode would be identified by a STIM prescription of any type, preceded by 3 months free of any other STIM. Thus, entry into the STIM category is more restrictive in that it excludes STIM initiations for patients who are moving among various categories of STIM therapies. In the LA-STIM example above, when the patient had taken IR methylphenidate within 3 months prior to starting the LA-STIM, the latter initiation would not be considered their "most recent" initiation of any STIM. For each comparison (ATX with STIMs, and ATX with LA-STIMs), patients were classified according to the most recent treatment initiation between the treatments being compared.
After categorizing patients according to their most recent pharmacological treatment initiation, selected demographic and historical diagnostic and treatment variables were assessed for the year prior to initiation for each patient (Table 2) . These included the presence of common medical and psychiatric disorders (as indicated by ICD-9-CM codes within service claims) and medication use (as indicated by National Drug Code codes on pharmacy claims) within the 1 year prior to treatment initiation. Behavioral health care utilization rates were also assessed by computing the per-patient frequency of claims reflecting services for behavioral or psychological therapies (Current Procedural Terminology codes 90804 through 90831, 90842-90857, 90875-90889, 90901-90910, or 96100), visits to nonprescribing mental health specialists (such as psychologists and social workers), and claims with revenue codes consistent with the provision of nonmedication mental health therapy services as described by the Centers for Medicare and Medicaid Services (revenue codes 914, 915, 916, or 918). Behavioral health care utilization rates were categorized into "never used," "1-12 visits," or ">12 visits" in the past year.
Initiators of ATX were compared with STIM and LA-STIM initiators, in turn, on the basis of prior-year demographic and clinical characteristics using multivariate logistic regression. To avoid any collinearity that would result from including both an assessment of psychiatric conditions and the medications used to treat them in the same model, separate models were used to examine the associations between treatment initiation and (1) diagnostic history and (2) treatment history when adjusted for demographics and other diagnoses or treatments. Unadjusted odds ratios were also computed for age and gender. All analyses were conducted using SAS version 8.2 for Unix (Cary, NC). Coverage restrictions such as maximum age limits and formulary status (e.g., copayment tier) of the drugs in this study were not recorded in the database and were not available for evaluation in this research.
■■ Results
A total of 133,134 patients were identified as receiving medication treatment for ADHD in 2003 and having an ADHD diagnosis anywhere within their administrative claim records. Limiting this group to patients who initiated therapy between April 1, 2003, and December 31, 2003, and who had continuous enrollment for 1 full year preceding a treatment initiation resulted in 46,396 (34.8%) patients. Restricting the sample further to patients aged ≥18 years resulted in 10,359 patients (7.8%). The distribution of "most recent initiations" for these patients is shown in Table 3 . Note that because the inclusion criteria for initiation requires the nonuse of similar drugs for 3 months preceding a prescription, there are more disqualifications for initiations of STIMs generally than for LA-STIMs specifically. Since each patient is categorized according to his or her most recent therapy initiation, this results in a greater number of ATX initiators for the analyses comparing ATX with STIM use than for those comparing ATX with LA-STIM use. Table 2 shows the frequency distributions for demographic factors and past-year diagnostic and treatment history for ATX compared with STIM and LA-STIM initiations. Specific testing of these relationships was done within the adjusted logistic regression models. Compared with our predefined arbitrary referent category of patients aged 25 to 44 years, younger adults (18-24 years) showed a decreased likelihood of receiving ATX relative to both STIMs and LA-STIMs whereas no significant difference was noted for older (45+ years) adults. While no significant gender differences were observed in unadjusted analyses (Table 4) , females were less likely to receive ATX than STIMs and LA-STIMs in adjusted models.
Demographics and Past-Year Diagnostic and Treatment History for Initiations of Atomoxetine and Stimulant Therapies
Diagnostic history was informative in treatment selection. Figure 1 depicts the diagnoses assessed within claims along with the corresponding adjusted odds ratios for ATX initiation and associated 95% confidence intervals. For the broader comparison of ATX with STIMs, but not always when comparing ATX with LA-STIMs, patients with past-year claims for alcohol and drug dependence, psychosis, bipolar disorder, and anxiety disorders were more likely to initiate treatment with ATX, whereas patients with past-year claims for personality disorder were more likely to initiate treatment with STIMs or LA-STIMs. Though the rate of tics or Tourette' s was nearly 3 times higher for ATX initiators than STIM initiators, the overall past-year prevalence of this condition (<1%) was too low for this difference to reach significance in the adjusted models.
The direction of effect for all diagnostic predictors of ATX versus LA-STIM initiation was the same as for the comparison with STIM. However, drug dependence, psychosis, and anxiety disorders-all significant positive predictors of ATX versus STIM initiation-were not significantly associated with ATX The findings for historical medication use ( Figure 2 ) only partly replicated the diagnostic history results. For example, antipsychotic use, like a historical diagnosis of a psychotic disorder, was significantly associated with an increased likelihood of initiating ATX as opposed to STIMs. However, while antidepressant use in the treatment model was significantly associated with ATX initiation compared with both STIM and LA-STIM initiation, this relationship was not evident for depression in the diagnosis models. Use of bupropion, indicated for major depression but commonly used off-label for treatment of adults with ADHD, was similarly associated with an increased likelihood of initiating ATX. This trend is similar to-and may, in fact, be simply a reiteration of-the trends for other antidepressants. Conversely, prior antimanic medication use was not associated with treatment selection, whereas a bipolar/mania diagnosis was. A past-year STIM prescription was associated with an increased likelihood of resuming STIMs; this was true for both STIMs and for LA-STIMs specifically.
* "Qualifying initiations" are pharmacy claims preceded by a 90-day period free of a pharmacy claim for the same or similar drug. See "Methods" for details and example. † The ATX to LA-STIM analysis excludes patients treated primarily with medications other than ATX or LA-STIM, resulting in greater overall exclusion than for the ATX to STIM analysis. ADHD = attention-deficit/hyperactivity disorder; ATX = atomoxetine; LA-STIM = long-acting stimulant; STIM = stimulant.

Unadjusted Association Between Patient Demographics and Atomoxetine Treatment Selection
Using "no prior-year visits" as a reference category, prior use of behavioral services up to a once-monthly average rate was associated with significantly higher odds of initiating ATX as opposed to STIMs. Behavioral service utilization, however, did not predict treatment selection between ATX and LA-STIMs.
■■ Discussion
Our findings demonstrate that in adults with ADHD, a statistically significant association was found between some demographic characteristics and clinical history, and the initiation of treatment with a STIM versus ATX.
Our first hypothesis, that ATX would be used more often in patients with conditions potentially exacerbated by STIMs, was partially supported. ATX use was more common than STIM use in patients with anxiety, but it was not more common than LA-STIM use. ATX was also not associated with preferred use in patients with tic disorders. The second hypothesis, that patients at risk for substance abuse would be less likely to initiate STIMs, likewise received partial support. ATX was preferred over STIMs and LA-STIMs in patients with histories of alcohol dependence but not in patients with histories of nondependent drug abuse. Drug-dependent patients were more likely to initiate ATX over STIMs, but there was no difference between ATX and LA-STIM use.
The third hypothesis, that difficult-to-treat patients with psychiatric comorbidities or recent counseling would more frequently initiate ATX, was also only partially supported. ATX use was more likely in patients with psychosis, bipolar disorder, or anxiety (though in the latter 2 instances the effect was present only for STIMs, not for LA-STIMs), while STIMs were associated with increased preference in patients with personality disorder. Patients who have recent prescriptions for antidepressants or antipsychotics were slightly more likely to initiate ATX. ATX was not initiated more frequently in patients with prior depression or in those patients currently taking antimanic or anxiolytic medication. With respect to recent counseling, the use of behavioral services was positively associated with increased likelihood for ATX initiation relative to STIMs in general, but this distinction was not found for ATX use relative to LA-STIM use specifically.
While the above is somewhat consistent with our expectations, some patient factors associated with STIM initiation are more Adjusted Odds Ratios for Atomoxetine Initiation Based on Diagnostic History and Demographics , and personality disorders were all associated with increased odds of receiving STIMs. If we make the assumption that women are more likely than men to be interested in weight loss, the finding with regard to gender may reflect a preference for STIM treatment among women (without a formal diagnosis of obesity) inclined to view the anorexic effects of STIMs as an added benefit of treatment.
We can imagine 2 possible reasons that younger adults with ADHD would be more likely to prefer STIMs over ATX than older adults with ADHD. The first is the increasing acceptance of ADHD in adults as a treatment focus in recent years. 17 As medication treatment rates have increased along with recognition of the persistence of ADHD into adulthood, the predominance of STIM use in this age group may reflect an extension of the dominance of STIM use prior to the introduction of nonstimulant alternatives. 18 This might also reflect an extension of prior patient experiences, to the extent that patients who had used STIMs successfully during childhood might be more inclined to reinitiate therapies previously found to be beneficial. The significant extent to which we observed that past-year STIM use could predict new initiations is certainly consistent with that idea. Older adults initiating treatment may not have as much personal history with ADHD treatment and thus come into the treatment decision with a "cleaner slate."
A more pessimistic interpretation of this finding might be that this relationship is a reflection of the desire to divert STIM medications for abuse within the young adult population. 19, 20 Although diverted STIMs must ultimately have come from someone, the current data do not assess whether the patients who filled their prescriptions are the same people who are using or selling their medication. Future research would be needed to examine the supply side of diversion to understand to what degree prescriptions that are intended for insured persons in this age group end up in the hands of others.
With concerns over the diversion of prescription STIMs, [21] [22] [23] we expected patients with substance-abuse histories to be directed away from STIMs, given their potential for abuse. 24 We were, therefore, somewhat surprised to see that an overt history of nondependent drug abuse was not associated with medication selection. The more severe diagnoses of drug and alcohol dependence, however, did show a relationship in the expected direction (though the difference was not statistically significant in favor of ATX versus LA-STIMs for drug dependence).
The preference for STIM therapy in patients with personality disorders is more obscure, insofar as there is no obvious clinical reason that such patients should preferentially receive either therapy. It is possible that certain providers (e.g., psychiatrists) are both more likely to diagnose and/or code for personality disorders than other providers (e.g., primary care physicians) and more likely to use STIMs. 21 If so, the observed treatment difference for patients with personality disorders could simply reflect unmeasured practice variation.
Patients who were prior users of psychological or behavioral health care services showed mixed results. They were more likely to be treated with ATX than general STIMs, but no preference was seen for ATX over LA-STIMs specifically.
Limitations
Our methods of patient selection may have resulted in the inclusion of some patients without ADHD since coding errors would go unnoticed in the absence of thorough medical record reviews. Such coding errors, if present, may also result in the exclusion of true ADHD patients. Although we did not measure the rate of recording errors in our database, the large sample size leads us to believe that such unrecorded errors did not introduce any systematic bias when comparing the treatments of interest. We therefore believe that our analysis provides a reasonable characterization of the differences in how these medications are being prescribed in managed care settings. While the current methodology cannot prove cause and effect and does not address the relative effectiveness of the treatment alternatives studied, it does highlight the relative associations between clinical factors and medication choices that have emerged during the first year of ATX' s availability.
A further limitation is the availability of data on systemic factors that may affect care-for example, the rate of dispensation through mail-service pharmacies, plan limits such as noncoverage of STIMs in adults, or the formulary tier status of the drugs under study. Because our database contained information from many diverse health plans, a broad range of these and other systemic Similarly, the effect of provider specialty was unmeasured because of limitations in our ability to confidently determine provider specialty from claims. Often, the "provider" was not an individual specialist but a clinic that may have contained providers of diverse specialties. In addition, where specialty could not be clearly identified, the PharMetrics database imputed this based on practice patterns; as a result, the "psychiatric" specialty may in fact represent psychiatrists, psychologists, and social workers. To avoid statistical confounding with our "behavioral care" variable, we chose to omit provider specialty as an independent variable for this study.
Besides limited information on systemic factors affecting care, the exclusion of bupropion and tricyclic antidepressants leaves unexamined the utilization patterns of these commonly used agents for adult ADHD. As with other nonstimulants (with evidence supporting off-label use in adult ADHD), further research is merited.
Our study shares the limitations of all research conducted using administrative claims. As administrative rather than research tools, claims cannot be considered as accurate or reliable as the data derived from cohort clinical trials that follow patients over time; our data are observational and cannot provide insights into cause and effect.
■■ Conclusions
To our knowledge, this is the first examination of emerging patterns of treatment with ATX and STIMs for adults with ADHD; previously published research examined initiation of ATX and STIMs in children and adolescents with ADHD. The significance of patient demographics, clinical histories, and prior behavioral service use suggest that ATX and STIMs may be used for different purposes in the treatment of adults with ADHD. Future research into health service utilization patterns and outcomes, including relative effectiveness over time for ATX versus STIMs, should consider potential differences between patients receiving these treatment alternatives.
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